Hepatic impairment No dose adjustment is necessary in individuals with moderate or reasonable (Child-Pugh A or B) hepatic impairment (see area five.2). Publicity to midostaurin and its active metabolite CGP62221 is considerably lower in sufferers with critical hepatic impairment than that in patients with standard hepatic function (see area 5. https://nathaniell666ias7.wikiap.com/user